WebJan 23, 2024 · Astellas Transfers MYCAMINE® Product Worldwide. Published: Jan 23, 2024. TOKYO, Jan. 23, 2024 /PRNewswire/ -- Astellas Pharma US, Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that Astellas and Sandoz AG ("Sandoz") have entered into an Asset Purchase Agreement, under which … WebJan 23, 2024 · MYCAMINE ® (Generic Name: micafungin sodium/product name in Japan: FUNGUARD ®) Sales of the product JPY 18.9 billion (fiscal year ended March 31, 2024) Astellas is reviewing potential...
Astellas Stock Replacement Program For Mycamine
WebJan 8, 2024 · NORTHBROOK, Ill., Jan. 8, 2024 / PRNewswire / -- Astellas Pharma Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for MYCAMINE ® (micafungin for injection) in support of the treatment of Candidemia, Acute Disseminated Candidiasis, Candida … WebAstellas Stock Replacement Program For Mycamine, a patient assistance program provided by Astellas Pharma Inc., offers Mycamine at no cost to those who are eligible for the program. Eligibility is based off of the following requirements: You must be a citizen of the United States or its Territories. i cant battle gym in pokemon go 2018
Astellas Pharma 00469321110 - McKesson Medical-Surgical
WebJan 24, 2024 · Astellas reported Mycamine ® sales of JPY 18.9 billion (USD 135 million) for the year ending March 31, 2024. The announcement comes after Sandoz successfully completed the acquisition of GSK’s global cephalosporins portfolio in October 2024. WebMar 4, 2024 · Additional pediatric use information is approved for Astellas Pharma US, Inc.'s Mycamine ® (micafungin for injection). However, due to Astellas Pharma US, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information. 12.4 Microbiology Mechanism of Action. WebMar 31, 2024 · Mycamine is indicated for: Adults, adolescents ≥ 16 years of age and elderly treatment of invasive candidiasis; treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate; i cant be bothered in french